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Basal cell carcinoma (BCC) remains the most common form of nonmelanoma skin cancer (NMSC) in Caucasians, with perhaps
as many as 2 million new cases expected to occur in the United States in 2010. Many treatment options, including surgical
interventions and nonsurgical alternatives, have been utilized to treat BCC. In this paper, two non-surgical options, imiquimod
therapy and photodynamic therapy (PDT), will be discussed. Both modalities have demonstrated acceptable disease control rates,
cosmetically superior outcomes, and short-term cost-eﬀectiveness. Further studies evaluating long-term cure rates and long-term
cost eﬀectiveness of imiquimod therapy and PDT are needed.
1.Introduction
Basal cell carcinoma (BCC) remains the most common
cutaneous malignancy in Caucasians, with as many as 2
million new cases expected to occur in the United States
in 2010 [1–6]. Although surgical excision remains the
standard treatment for BCC, nonsurgical modalities also
have achieved acceptable cure rates [2]. Several factors may
inﬂuence the decision to pursue nonsurgical alternatives,
including lower overall costs and more cosmetically accept-
able outcomes. In this paper, we will discuss two nonsurgical
modalities for BCC treatment, topical imiquimod therapy,
and photodynamic therapy.
2. Topical Imiquimod Therapy
Imiquimod (1-(2 methylpropyl)-1 H-imidazo (4, 5c)
quinolin-4amine)isanimmunomodulatorwhichstimulates
the innate immune response via the upregulation and
release of cytokines such as IFN-alpha, IL-6, and TNF-
alpha as well as upregulating natural killer cell activity
and upregulating nitric oxide secretion from macrophages
[7, 8]. Imiquimod also upregulates the cell-mediated
immune response through indirect stimulation of the Th1
cytokine IFN-gamma and activation of Langerhans cells
to promote antigen presentation [9]. In vitro, imiquimod
induces cytokine production via activation of Toll-like
receptor 7 (TLR7), which in turn activates nuclear factor
kappa B to stimulate production of IFN-alpha and cytokines
IL-12 and IL-18. These cytokines then induce IFN-gamma
production by na¨ ıve T cells, resulting in a Th1-type immune
response. Thus, both IFN-alpha and IFN-gamma impart
antiviral and antitumor activity to imiquimod. In addition,
by stimulating cytotoxic T lymphocytes, IFN-gamma pro-
vides long-term immune memory. In essence, imiquimod
stimulates both the innate and the cell-mediated arms of the
immune system [10].
Imiquimod has been approved in the United States by
the FDA for the treatment of superﬁcial BCC (sBCC) in
immunocompetent adults with tumors >0.5cm2 in area and
<2cm in diameter located on the trunk and extremities [11].
Previous studies have utilized imiquimod 5% cream with
application schedules ranging from 5 days to 7 days per week
for 6–12 weeks. Studies also have reported the use of topical2 Journal of Skin Cancer
imiquimod to treat other BCC subtypes such as nodular
BCC (nBCC) and sclerodermiform BCC [12–18]. One study
demonstratedthat,ina2-yearfollowupof55patientstreated
with imiquimod, 41 (74%) had complete remission (4/4
sBCCs(100%);7/8nBCCs(88%)and30/43inﬁltrativeBCCs
(70%)) [18]. In addition, imiquimod has also been explored
as adjuvant therapy for patients after undergoing surgical
treatment for nodular and superﬁcial BCC [19–21].
Karve et al. recently compiled a summary of clinical
trials evaluating the eﬃcacy of imiquimod 5% cream in the
treatmentofsBCC,withtheprimarygoalbeingtheclearance
of the tumor as detected by clinical and/or histological
examinations [22]. Data from large randomized clinical
trials demonstrated imiquimod 5% cream to be statistically
superiortoplacebointreatingsBCC[22].Theclearancerates
ranged from 75%–80.8% for patients treated 5 days/week
and 73%–87.1% for patients treated 7 days/week. However,
these clearance rates are signiﬁcantly lower than those rates
achieved by surgical methods [10].
No placebo-controlled, double-blind trials have eval-
uated the long-term sustained clearance of BCC after
imiquimod therapy by utilizing an excisional biopsy of
the treated site for histologic examination to document
tumor eradication [22]. However, two phase 3 clinical
trials, conducted in Europe and Australia/New Zealand,
were designed to evaluate long-term clearance and both
demonstratedsimilarinitialclearancerates[23,24].Forboth
ofthesestudies,theestimated2-yearclearancewascalculated
by multiplying the initial 12-week clearance rate with the
estimated nonrecurrence rates obtained from the life-table
method [22]. Thus, 79.4% and 88.7% of the imiquimod
recipients, respectively, were reported to be tumor-free two
years posttreatment [23, 24].
In all the studies evaluating the eﬃcacy of imiquimod
5% cream in the treatment of sBCC, over 50% of patients
reported at least 1 adverse event during the study period
[22]. The most frequently reported adverse event was a local
application site reaction, such as itching, irritation, burning,
tenderness, and hypopigmentation [22]. Patient compliance
was deﬁned either as situations in which patients applied at
least80%oftherequireddoseorinwhichpatientscompleted
the prescribed dosing schedule [22]. The compliance of
patients to the imiquimod therapy ranged from 60% to 98%
[13, 18, 25].
Although surgical procedures such as surgical excisions,
Mohs micrographic surgery, and curettage and electrodessi-
cation (C&E) comprise the current mainstay of surgical
treatments of BCC, these procedures do not ensure 100%
eradication of the tumor [6, 26]. Nodular BCC and sBCC are
typically treated with surgical excision and C&E procedures.
Furthermore, while C&E is frequently utilized to treat small
tumors <1.5cm in diameter, Mohs micrographic surgery
addresses large tumor sizes >2cm [22]. A range of 5-year
recurrence rates after surgical excision have been reported
to be from 0.7% to 10.1%, while the recurrence rates after
C&E range from 3.3 to 7.7% [22]. In fact, the incidence of
incomplete excision varies from 4.7% to 10.8% [27–29]. The
purpose of employing imiquimod as adjunctive therapy for
surgical excisions is twofold: to remove any residual tumor
and to improve the cosmesis of the wound [21, 26, 30–
34]. The inﬂammation induced by imiquimod may aid in
the clearance of BCC [30]. Furthermore, imiquimod has
been demonstrated to improve photoaging skin by increas-
ing ﬁbroplasia, decreasing elastosis, and restoring pigment
[35].
In one study, topical imiquimod 5% cream after C&E
of nodular BCC (n = 10) daily for 1 month resulted
in fewer patients with residual tumor present at 8 weeks
(10%) compared to control patients (40%). Furthermore,
another larger study (n = 34) evaluated the eﬃcacy of
imiquimod 5% cream following curettage only of nodular
BCC on the trunk and extremities [32]. 94% of the treated
lesions showed histologic eradication of BCC. An earlier
analysisrevealederadicationratestobeashighas96%after3
years [21]. Therefore, the regimen of curettage with adjuvant
imiquimod therapy may be considered to be an alternative
treatment option of nodular BCC that additionally provides
cosmetic advantages.
There are very few studies comparing the cost-
eﬀectiveness of surgical treatment versus topical imiquimod
therapy for sBCC. One 2007 study estimated the mean
cost per patient treated with imiquimod 5% therapy (5
times/week for 6 weeks) to be lower than that of a patient
treated with surgical excision for a single sBCC lesion
less than 2cm in diameter (C621 versus C676, resp.)
[36]. However, one limitation of the study was that the
costs associated with treating initial treatment failures or
recurrences during long-term followup were not addressed.
Another study compared the cost-eﬀectiveness of imiqumod
therapy versus surgical treatment of sBCC and reported that
although imiquimod was more cost-eﬀective in the short
term (total costs: imiquimod C585 versus surgery C663), it
was more expensive in the long term (total costs: imiquimod
C1471 versus surgery C1322) [37]. However, the study
limitationisthattherewerenocalculatedestimatedeﬃcacies
of imiquimod therapy provided. Sverre et al. contrasted
the cost-eﬃcacy of imiquimod to the broad category of
standard-of-care treatments (surgical excision, cryosurgery,
or photodynamic therapy (PDT)) for sBCC [38]. The cost
of imiquimod therapy was higher (by C16) than that of the
latter category. Imiquimod however was found to be more
cost-eﬀective than PDT treatment, and was demonstrated to
have a better outcome, albeit higher cost, than cryosurgery.
To date, the long-term cost-eﬀectiveness of imiquimod and
its impact on the quality of life of patients with sBCC has not
been comprehensively studied.
3. Photodynamic Therapy
BCC remains the most frequent oncologic application of
PDT [39–41]. Although ﬁrst described roughly a century
ago, PDT did not spawn careful clinical investigation until
the 1960s. Subsequently, PDT has been utilized in a wide
variety of conditions, ranging from oncologic entities such
as BCC and mycoses fungoides, to acne and psoriasis [42].
Photodynamic therapy utilizes oxygen radicals generated
from a photoactive molecule to achieve a therapeutic tissueJournal of Skin Cancer 3
response. This photochemical reaction requires a pho-
toactivating light, a photosensitizer, tissue oxygen, and a
target cell. In this process, photon energy is converted to
oxygen singlets, which then mediate target cell injury and
death. Photosensitizers may be administered systemically or
topically (as a prophotosensitizer). The mode of delivery
determines tissue localization.
Systemic photosensitizers, whether delivered via oral
or intravenous routes, are comprised of large intact and
lipophilic macrocytes which avidly bind to serum lipopro-
teins, chieﬂy the low-density lipoproteins (LDLs). These
photosensitizers include porﬁmer, benzoporphyrin deriva-
tive monoacid ring A (BPD-MA), metatetrahydroxyphen-
ylchlorin (mTHPC, temoporﬁn), and tin ethyl etiopurpurin
(SnET2) [42]. In addition, tissue macrophages and tumor
cells retain these photosensitizers, which contribute to
the long-lasting photosensitivity that persists after their
administration. In contrast, the prophotosensitizers are low-
molecular weight, hydrophilic and are topically adminis-
tered onto the aﬀected skin surface. These include 5-delta-
aminolevulinic acid HCL (ALA) and methyl-esteriﬁed ALA
(mALA). In the latter case, the stratum corneum of the
skin is typically removed via superﬁcial curettage prior
to mALA topical application. After absorption, mALA is
then metabolized to ALA, upon which it is easily absorbed
through the cell membrane.
The gold standard of a photosensitizer is one which
maintains reduced tissue retention so that there is a
decreased risk of prolonged systemic photosensitivity. Pro-
toporphyrin IX (PpIX) maintains a high tissue retention due
to its hydrophobic qualities. However, the administration of
a prophotosensitizer, such as ALA, enables cells to produce
PpIX themselves for photoactivation. Since 1987, BCC,
actinic keratoses (AKs), and squamous cell carcinoma (SCC)
have been treated with topical ALA and red light [43, 44].
PDT received FDA approval in 1999 for the treatment of AKs
utilizing topical ALA plus blue light.
The eﬀectiveness of PDT responses depends upon
the tissue localization of photosensitizers. Following drug
administration, adequate time must be allowed for proper
distribution of the photosensitizers to the target tissues. Ide-
ally, photoactivation should occur when the photosensitizer
concentration in the target tissue exceeds that in the normal
tissue in order to achieve the maximum eﬃcacy of PDT.
In order to minimize tissue penetration of ultraviolet
(UV) light and the subsequent risk of incurring skin cancers,
the PDT wavelength utilized for treatment must be longer
than those in the UV spectrum. Thus, the PDT wave-
length range is between 400 and 800nm. Increased tissue
penetration correlates with increased wavelength; therefore,
blue light provides adequate penetration for treating epider-
mal lesions. In contrast, dermal lesions necessitate deeper
penetrating red light that must correspond with one of
the photosensitizer’s absorption peaks. Visible light from
noncoherent or coherent (laser) sources is used. The two
types of light include low-power, continuous wave, and
nonthermal versus high-power, pulsed and photothermal.
The latter light type utilizes biologic chromophores (i.e.,
melanosomes, blood vessels, etc.) to amplify tissue injury.
Inordertosuccessfullytreatcutaneousmalignancies,and
premalignancies with PDT, the minimum “photodynamic
dose,” or threshold of injury, must be achieved in order
to induce a degree of cell destruction which cannot be
reversed through inherent cell repair processes. Conse-
quently, PDT induces intense inﬂammation through the
release of cytokines, chemokines and other immunologic
proteinsbytheinjuredandapoptoticcells.PDThasalsobeen
demonstrated to act as a biologic response modiﬁer [45].
In addition to damaging target cells directly, PDT, through
upregulated cytokine production, enhances the innate and
adaptive immune responses in immunocompetent individu-
als [45].
Although PDT is commonly utilized to treat BCC,
there exist few studies which directly compare the eﬃcacy
of PDT against the standard treatment modalities such
as surgical excision, Mohs surgery, or cryosurgery. There
is evidence that systemic porphyrin-based PDT induces a
complete response in 80% to 100% of BCC cases, but no
long-term followup was performed [46–48]. Selected studies
utilizing systemic photosensitizers (porﬁmer sodium, BPD-
MA and meta-tetrahydroxyphenylchlorin [mTHPC]), and
red light were analyzed [49–52]. Although good response
rates were achieved (78% to 88% range), signiﬁcant adverse
eﬀects included generalized photosensitivity, facial edema,
and severe pain during treatment and posttreatment [49–
52].Furthermore,higherdosesofphotosensitizerandhigher
light ﬂuences were associated with better response rates,
and mTHPC usage necessitated much shorter illumination
periods [42].
There is a desire to minimize the use of systemic
photosensitizers due to the aforementioned risks associated
with prolonged generalized photosensitivity. Consequently,
the topical photosensitizers (ALA, mALA) have gained favor
due to their decreased adverse eﬀects and their convenient
use. Early studies reported a 79% complete response rate
at 3 months for 300 sBCC treated with ALA 20% (3–
6 hours) using ﬁltered red (600+ nm) light [43, 44].
Subsequent studies utilizing topical ALA or mALA and red
light demonstrate superior response rates for sBCC than for
nodular BCC [53–56]. One study compared the therapies
of mALA-PDT with surgical excision (>5mm margins) of
nodular BCC and demonstrated complete response rates at
1 year of 83% and 96%, respectively [55].
Topical photodynamic therapy is generally well tolerated
[42]. Immediate eﬀects after treatment include erythema
and slight edema. After a few days, crusts and superﬁcial
erosions may be noted, and ulcerations are uncommon [57].
The most common acute side eﬀect experienced by patients
is pain, which has been described as a burning, stinging,
or prickly sensation in the ALA-treated sites during light
exposure [58]. The mechanism is unclear, but hyperthermia
related to the presence of a reactive singlet oxygen has been
implicated.
The pain associated with ALA-PDT is also related to
the site and size of the treated area [57]. The treatment of
facial and scalp lesions have been noted to be associated
with greater incidences of pain [57]. In instances involving
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impractical for PDT treatment of extensive regions. Case
r e p o rt sh a v ed o c u m e n t e dt h etr e a tm e n to fl a r g es u rf a c ea r e a s
(up to 22% BSA) over 3–6 hours under general anesthesia
in these patients [57, 58]. In children, general anesthesia has
been demonstrated to be safer than conscious sedation [57].
Pain management options incude local anesthesia, premed-
ication with opiod analgesics, cooling fans or spraying the
treated areas with water [57]. Cold air analgesia has been
found to be eﬀective in some cases; however, tetracaine gel,
capsaicin cream, and morphine gel have been found to be
ineﬀective [58].
Potential disadvantages of topical PDT in the treatment
of BCC include insuﬃcient drug delivery at depth or insuf-
ﬁcient light delivery at depth [38]. One study demonstrated
that although 69% of the topical ALA-treated tumors (BCC,
SCC in situ, invasive SCC) were clinically clear, only 46% of
thetreatedtumorswerehistologicallyclearduetosubclinical
extensionofthetumor[59].Thisﬁndingsuggeststhatcancer
recurrences following PDT may result from inadequate
penetration of topical ALA into the deep dermis. The
aggressive subtypes of BCC, including morpheaform BCC,
would demonstrate the least drug penetration due to their
intact stratum corneum.
Attempts to enhance tissue penetration of ALA and to
improve the cure rates of BCC treated with topical ALA PDT
include curettage of the tumor site immediately prior to ALA
application; pretreatment with dimethylsulfoxide (DMSO);
prolonged ALA application (up to 48 hours); intralesional
ALA injection [42]. In addition, ALA has been compounded
with ethylenediaminetetraacetic acid (EDTA) or desferriox-
amine to enhance PpIX formation. These protocols have
demonstrated improvement in long-term cure rates [42].
To address the drug penetration issue, modiﬁcations in
the ALA administration protocols have been utilized. For
example, studies using abbreviated systemic ALA adminis-
tration have used a single ALA dosage, or fractionated oral
ALA dosage (60mg/kg delivered in 20mg/kg increments)
and fractionated red light (600–650nm; 50 or 100J/cm2)t o
reduce the duration of generalized photosensitivity and to
circumvent transient liver enzyme elevation [42].
Topical mALA is more lipophilic than ALA and demon-
strates increased tissue penetration. In a retrospective review
(n = 350) of the treatment of BCC with mALA-PDT, the
initial complete response was conﬁrmed years later (mean 35
months) in 89% of the treated sites, with 11% recurrences
(both morpheaform BCCs recurred after treatment) [56].
Overall, the existing data suggest that mALA is an eﬀective
agent with PDT therapy and that nodular BCC may be more
responsive to mALA than to ALA [42].
In a study by Caekelbergh et al., cosmetic outcome was
deﬁned as excellent (no scarring, atrophy or induration and
no or slight occurrence of redness or change in pigmentation
compared to surrounding skin); good (no scarring, atrophy
or induration, but moderate redness or pigmentary change
compared to surrounding skin) fair (slight to moderate
occurrence of scarring, atrophy or induration), or poor
(marked occurrence of scarring, atrophy or induration)
[60]. The cosmetic outcomes from PDT were deemed to be
more favorable than those from standard surgical therapy
(margins >5mm) or cryotherapy [42]. Due to its ability to
treat large body surface areas with a single administration
and with minimal scarring, topical PDT is ideal to treat
patients with familial cancer syndromes including Gorlin
syndrome (nevoid basal cell carcinoma syndrome).
The cost-eﬀectiveness of PDT using mALA for sBCC was
addressed in a prospective, observational study (n = 90
patients) by Caekelbergh et al. [60]. The analysis revealed
a complete clinical response rate of 89% for sBCC 6
months after the ﬁrst mALA-PDT treatment. The study also
found that mALA-PDT was more cost-eﬀective than surgical
excision in the treatment of sBCC [60].
4. Conclusion
In summary, imiquimod therapy and PDT have been
demonstrated to achieve acceptable short-term cure rates
of BCC. Clearance rates of 73% to 87.1% have been
reported in patients with sBCC treated with imiquimod 5%
cream. Imiquimod is also an eﬀective adjuvant therapy in
patients with BCC treated with surgical treatments. Topical
photosensitizers are favored for use in PDT due to the lower
risk of adverse eﬀects, convenient use, and the ability to treat
largesurfaceareas.TopicalALA-PDThasbeendemonstrated
to achieve a clearance rate of 79% for sBCC. In addition to
treating sBCC, topical mALA-PDT also has been shown to
be eﬀective in treating nodular BCC due to its deeper tissue
penetration.
Due to their improved cosmesis, cost-eﬀectiveness, and
minimally invasive nature, these nonsurgical alternatives
may be considered for treatment of appropriate tumors,
especially sBCC. Long-term recurrence rates and safety of
imiquimod use and PDT use have yet to be determined.
Further studies evaluating the long-term parameters of
eﬃcacy, safety, and cost-eﬀectiveness of imiquimod therapy
and PDT are warranted.
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